CABELL CHRISTOPHER (President & Head of R&D) reported 1 transaction at INHIBIKASE THERAPEUTICS, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 2/24/2026ACC: 0001193125-26-068077
Officer· President & Head of R&D
Since Feb 2026
-338.28K
Net shares
Net seller
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
338.28K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−338.28K
Price / share
—
Trade value
—
% of position
33.3%
2/21/2026
1.01M→676.56K
Total
Net shares
−338.28K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/21/2026 | D · Disposition | −338.28K | — | — | 33.3% | 1.01M | 676.56K |
| Total | −338.28K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported